

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

IN RE: BRIMONIDINE PATENT)
LITIGATION)
) C.A. No. 07-MD-01866-GMS
)
)

NOTICE OF SUBPOENAS *AD TESTIFICANDUM* AND *DUCES TECUM*

PLEASE TAKE NOTICE that, pursuant to Rule 45 of the Federal Rules of Civil Procedure, defendants Apotex Inc. and Apotex Corp., have served or will serve the attached subpoenas *ad testificandum* and *duces tecum* (Exhibits A and B) on Bobby C. Danner and Bio-Cide International Inc., respectively.

POTTER ANDERSON & CORROON LLP

OF COUNSEL:

Robert B. Breisblatt
Stephen P. Benson
Joanna R. Stevason
Jeremy C. Daniel
KATTEN MUCHIN ROSENMAN LLP
525 West Monroe Street
Chicago, Illinois 60661-3693
Tel: (312) 902-5480

Dated: September 4, 2008
881128 / 31920 (MDL)

By: /s/ David E. Moore
Richard L. Horwitz (#2246)
David E. Moore (#3983)
Hercules Plaza 6th Floor
1313 N. Market Street
P.O. Box 951
Wilmington, DE 19899
Tel: (302) 984-6000
rhorwitz@potteranderson.com
dmoore@potteranderson.com

*Attorneys for Defendants
Apotex Inc. and Apotex Corp.*

EXHIBIT A

~~AO88 (Rev. 12/06) Subpoena in a Civil Case~~

Issued by the
UNITED STATES DISTRICT COURT
WESTERN DISTRICT OF OKLAHOMA

In Re: Brimonidine Patent Litigation

SUBPOENA IN A CIVIL CASE

v.

Case Number:¹ 07-MD-01866-GMS

TO: Bobby C. Danner
 3933 Charing Cross Ct.
 Norman, OK 73072

currently pending in the U.S.
 District Court for the District
 of Delaware

- YOU ARE COMMANDED to appear in the United States District court at the place, date, and time specified below to testify in the above case.

PLACE OF TESTIMONY	COURTROOM
	DATE AND TIME

- YOU ARE COMMANDED to appear at the place, date, and time specified below to testify at the taking of a deposition in the above case.

PLACE OF DEPOSITION	DATE AND TIME
Phillips McFall McCaffrey McVay & Murrah P.C. Corporate Tower / Thirteenth Floor, 101 N. Robinson, Oklahoma City, OK 73102	Sept. 23, 2008 9:30 a.m.

- YOU ARE COMMANDED to produce and permit inspection and copying of the following documents or objects at the place, date, and time specified below (list documents or objects):

See Schedule A.

PLACE	DATE AND TIME
Mr. Fred Leibrock, Phillips McFall McCaffrey McVay & Murrah P.C. Corporate Tower / Thirteenth Floor, 101 N. Robinson, Oklahoma City, OK 73102	Sept. 17, 2008
<input type="checkbox"/> YOU ARE COMMANDED to permit inspection of the following premises at the date and time specified below.	
PREMISES	DATE AND TIME

Any organization not a party to this suit that is subpoenaed for the taking of a deposition shall designate one or more officers, directors, or managing agents, or other persons who consent to testify on its behalf, and may set forth, for each person designated, the matters on which the person will testify. Federal Rules of Civil Procedure, 30(b)(6).

ISSUING OFFICER'S SIGNATURE AND TITLE (INDICATE IF ATTORNEY FOR PLAINTIFF OR DEFENDANT)	DATE
(Attorney for Defendant)	Sept. 3, 2008
ISSUING OFFICER'S NAME, ADDRESS AND PHONE NUMBER	
Johanna Stevason, Katten Muchin Rosenman LLP, 525 W. Monroe St., Chicago, IL 60661 (312) 902-5200	

(See Rule 45, Federal Rules of Civil Procedure, Subdivisions (c), (d), and (e), on next page)

¹ If action is pending in district other than district of issuance, state district under case number.

AO88 (Rev. 12/06) Subpoena in a Civil Case

PROOF OF SERVICE

DATE	PLACE
SERVED 9/3/2008	1717 Main Street, Suite 5000, Dallas, TX 75201
SERVED ON (PRINT NAME) W. Chad Shear (on behalf of Bobby Danner)	MANNER OF SERVICE Federal Express
SERVED BY (PRINT NAME) Joanna Stevason	TITLE Attorney

DECLARATION OF SERVER

I declare under penalty of perjury under the laws of the United States of America that the foregoing information contained in the Proof of Service is true and correct.

Executed on 9/3/2008
DATE



SIGNATURE OF SERVER

525 W. Monroe Street, Chicago, IL 60661

ADDRESS OF SERVER

Rule 45, Federal Rules of Civil Procedure, Subdivisions (c), (d), and (e), as amended on December 1, 2006:**(c) PROTECTION OF PERSONS SUBJECT TO SUBPOENAS.**

(1) A party or an attorney responsible for the issuance and service of a subpoena shall take reasonable steps to avoid imposing undue burden or expense on a person subject to that subpoena. The court on behalf of which the subpoena was issued shall enforce this duty and impose upon the party or attorney in breach of this duty an appropriate sanction, which may include, but is not limited to, lost earnings and a reasonable attorney's fee.

(2) (A) A person commanded to produce and permit inspection, copying, testing, or sampling of designated electronically stored information, books, papers, documents or tangible things, or inspection of premises need not appear in person at the place of production or inspection unless commanded to appear for deposition, hearing or trial.

(B) Subject to paragraph (d)(2) of this rule, a person commanded to produce and permit inspection, copying, testing, or sampling may, within 14 days after service of the subpoena or before the time specified for compliance if such time is less than 14 days after service, serve upon the party or attorney designated in the subpoena written objection to producing any or all of the designated materials or inspection of the premises—or to producing electronically stored information in the form or forms requested. If objection is made, the party serving the subpoena shall not be entitled to inspect, copy, test, or sample the materials or inspect the premises except pursuant to an order of the court by which the subpoena was issued. If objection has been made, the party serving the subpoena may, upon notice to the person commanded to produce, move at any time for an order to compel the production, inspection, copying, testing, or sampling. Such an order to compel shall protect any person who is not a party or an officer of a party from significant expense resulting from the inspection, copying, testing, or sampling commanded.

(3) (A) On timely motion, the court by which a subpoena was issued shall quash or modify the subpoena if it

- (i) fails to allow reasonable time for compliance;
- (ii) requires a person who is not a party or an officer of a party to travel to a place more than 100 miles from the place where that person resides, is employed or regularly transacts business in person, except that, subject to the provisions of clause (c)(3)(B)(iii) of this rule, such a person may in order to attend trial be commanded to travel from any such place within the state in which the trial is held;
- (iii) requires disclosure of privileged or other protected matter and no exception or waiver applies; or
- (iv) subjects a person to undue burden.

(B) If a subpoena

- (i) requires disclosure of a trade secret or other confidential research, development, or commercial information, or

- (ii) requires disclosure of an unretained expert's opinion or information not describing specific events or occurrences in dispute and resulting from the expert's study made not at the request of any party, or

- (iii) requires a person who is not a party or an officer of a party to incur substantial expense to travel more than 100 miles to attend trial, the court may, to protect a person subject

to or affected by the subpoena, quash or modify the subpoena or, if the party in whose behalf the subpoena is issued shows a substantial need for the testimony or material that cannot be otherwise met without undue hardship and assures that the person to whom the subpoena is addressed will be reasonably compensated, the court may order appearance or production only upon specified conditions.

(d) DUTIES IN RESPONDING TO SUBPOENA.

(1) (A) A person responding to a subpoena to produce documents shall produce them as they are kept in the usual course of business or shall organize and label them to correspond with the categories in the demand.

(B) If a subpoena does not specify the form or forms for producing electronically stored information, a person responding to a subpoena must produce the information in a form or forms in which the person ordinarily maintains it or in a form or forms that are reasonably usable.

(C) A person responding to a subpoena need not produce the same electronically stored information in more than one form.

(D) A person responding to a subpoena need not provide discovery of electronically stored information from sources that the person identifies as not reasonably accessible because of undue burden or cost. On motion to compel discovery or to quash, the person from whom discovery is sought must show that the information sought is not reasonably accessible because of undue burden or cost. If that showing is made, the court may nonetheless order discovery from such sources if the requesting party shows good cause, considering the limitations of Rule 26(b)(2)(C). The court may specify conditions for the discovery.

(2) (A) When information subject to a subpoena is withheld on a claim that it is privileged or subject to protection as trial-preparation materials, the claim shall be made expressly and shall be supported by a description of the nature of the documents, communications, or things not produced that is sufficient to enable the demanding party to contest the claim.

(B) If information is produced in response to a subpoena that is subject to a claim of privilege or of protection as trial-preparation material, the person making the claim may notify any party that received the information of the claim and the basis for it. After being notified, a party must promptly return, sequester, or destroy the specified information and any copies it has and may not use or disclose the information until the claim is resolved. A receiving party may promptly present the information to the court under seal for a determination of the claim. If the receiving party disclosed the information before being notified, it must take reasonable steps to retrieve it. The person who produced the information must preserve the information until the claim is resolved.

(e) **CONTEMPT.** Failure of any person without adequate excuse to obey a subpoena served upon that person may be deemed a contempt of the court from which the subpoena issued. An adequate cause for failure to obey exists when a subpoena purports to require a nonparty to attend or produce at a place not within the limits provided by clause (ii) of subparagraph (c)(3)(A).

SCHEDULE A

Definitions and Instructions

1. **'078 Patent.** The term “ ‘078 Patent” means U.S. Patent No. 5,424,078.
2. **‘640 Application.** The term “ ‘640 Application” means U.S. Patent Application No. 694,640 filed May 2, 1991.
3. **‘791 Application.** The term “ ‘791 Application” means U.S. Patent Application No. 277,791 filed Nov. 29, 1988.
4. **‘790 Application.** The term “ ‘790 Application” means U.S. Patent Application No. 277,790 filed on Nov. 29, 1988.
5. **‘126 PCT Application.** The term “ ‘126 PCT Application” means PCT Application No. WO 90/06126 filed Nov. 22, 1989 and published on June 14, 1990.
6. **Allergan.** The term “Allergan” refers to Allergan, Inc. and any related entities, partners, corporate parents, subsidiaries, affiliates, as well as any of their present or former officers, directors, employees, agents, representatives, attorneys and persons acting or purporting to act on their behalf. Where applicable, this definition shall include all persons having a former or current ownership interest in the ‘078 Patent, the ‘791 Application, and/or the ‘640 Application.
7. **Bio-Cide.** The term “Bio-Cide” refers to Bio-Cide International, Inc., Bio-Cide Chemical Co. Inc., and any related entities, partners, corporate parents, subsidiaries, affiliates, as well as any of their present or former officers, directors, employees, agents, representatives, attorneys and persons acting or purporting to act on their behalf. Where applicable, this definition shall include all persons having a former or current ownership interest in the ‘790 Application and/or the ‘126 PCT Application.

8. **Communication.** The term "communication" means the transmittal of information in the form of facts, ideas, inquiries, or otherwise.
9. **Concern(s), Concerning, Concerned with, Relate(s) or Relating to.** The terms "concern(s)", "concerning", "concerned with", "relate(s)", or "relating to" are used interchangeably and mean concerning, evidencing, pertaining to, referring to, mentioning, memorializing, commenting on, containing, identifying, connected with, contemplating, discussing, stating, describing, reflecting, dealing with, consisting of, constituting, comprising, recording, or being relevant to all or any portion of the specified fact, conditions, events, or incidents.
10. **Date.** The term "date" means the exact day, month, and year, if known or ascertainable; if the exact day, month, and year are not known or ascertainable, the most accurate temporal reference available.
11. **Document.** The term "document" is synonymous in meaning and equal in scope to the usage of this term in Federal Rule of Civil Procedure 34(a), including, without limitation, electronic or computerized data compilations. A draft or non-identical copy is a separate document within the meaning of this term. "Document" also includes and refers to the file or any container which once held any documents, as well as to any writing or printing which might appear on such file or container.
12. **Inventor(s).** The term "inventor" or "inventors" means the named inventor(s) of the '078 Patent, the '640 Application, the '791 Application, the '790 Application, the '126 PCT Application, Anthony J. Dziabo, Paul S. Ripley, Bobby C. Danner, and/or Persons with a past or present ownership interest in the '790 Application, the '126 PCT Application and/or the application which matured into the '078 patent and/or the '078

patent itself, including, without limitation, Allergan and/or Bio-Cide and (i) all their predecessors-in-interest and successors-in-interest; (ii) all past or present corporate parents, subsidiaries, affiliates divisions, officers, directors, employees, agents, consultants, investigators, attorneys, and representatives; (iii) any other person acting on their behalf or on whose behalf they have acted or are acting; or (iv) any other person or entity otherwise subject to their control or which controls or controlled them.

13. **Person.** The term “person” is defined as any natural person or any business, legal or governmental entity or association, and any functional division thereof.
14. **You.** The term “you” or “your” refers to Bobby Danner and any of his past or present employees, agents, representatives, or attorneys acting on his behalf with knowledge, possession, custody or control of any documents relating to the ‘078 Patent, the ‘791 Application, the ‘640 Application, the ‘790 Application, and/or the ‘126 PCT Application.
15. The following **rules of construction** apply to these document requests, definitions, and instructions:
 - (a) **All/Each/Any.** The terms “all”, “each”, and “any” shall be construed as inclusive and synonymous and are as inclusive in scope as permitted by the Federal Rules of Civil Procedure.
 - (b) **And/Or.** The connectives “and” and “or” shall be construed either disjunctively or conjunctively as necessary to bring within the scope of the request all responses that might otherwise be construed to be outside of its scope.
 - (c) **Number.** The use of the singular form of any word includes the plural and vice versa.

- (d) **Independence.** Except as otherwise expressly directed herein, each paragraph and subparagraph of a document request shall be construed independently and not by reference to any other paragraph or subparagraph herein for the purpose of limiting the scope of the document request being responded to.
16. Each request to produce documents shall be construed to request documents within your possession, custody, or control. Separately, for each Request, if any document responsive to that Request once was in your possession, custody, or control but has been lost, discarded, destroyed, or is otherwise presently not within your possession, custody, or control:
- (a) identify the unavailable document;
 - (b) identify any and all persons who lost, discarded, or destroyed the document or caused the document to become otherwise unavailable;
 - (c) identify any and all persons likely to have knowledge concerning the circumstances by which the document was lost, discarded, destroyed, or otherwise became unavailable; and
 - (d) identify any and all persons likely to have knowledge concerning the contents of the document that was lost, discarded, destroyed, or otherwise became unavailable.
17. When producing documents, you should organize and label them to correspond with the numbered categories in this request and where applicable, the order and organization of documents within each category should reflect the manner in which such documents are maintained in the usual course of business.

18. Please produce all documents maintained or stored electronically in native, electronic format with all relevant metadata intact and in appropriate useable manner. Encrypted or password protected documents should be produced in a form permitting them to be reviewed.
19. If you find the meaning of any terms in these requests unclear, you shall assume a reasonable meaning, state what the assumed meaning is, and respond to the request according to the assumed meaning.
20. If you object to any request or part of any request, the reason(s) for the objection shall be stated in full. If an objection is made to any request, production should be made of all documents or things to which the objection does not relate.
21. If you withhold any information, document, or thing otherwise discoverable under the Federal Rules of Civil Procedure on the basis of privilege and/or the work product doctrine, the following information is requested:
 - (a) the privilege and/or work product rule of law being relied upon;
 - (b) the date the document was created;
 - (c) the identity of the person or persons who created the information, document or thing;
 - (d) the identity of the present custodian of the information, document or thing; and
 - (e) the identity of any and all persons to whom the information, document, or thing was or has been sent, distributed, forwarded, copied, told, or communicated in any manner, stating the job title and/or position of that person;
 - (f) the subject matter of the information, document or thing; and
 - (g) the location of the information, document or thing.

DOCUMENT REQUESTS

A. The '078 Patent

1. All documents concerning the '078 Patent in your possession, custody, or control.
2. All documents contained in any file relating to the '078 Patent.
3. All documents and communications that refer or relate to the preparation and/or prosecution of the '078 Patent and/or any U.S. applications or foreign applications that constitute or are based in whole or in part on, or which claim priority from, or are the basis of priority for, any of the applications in the family of patent application leading to the '078 Patent (including the '791 and '640 Applications) and any related opposition, re-examination, and/or reissue proceedings, including, without limitation:
 - (a) all documents that provided the bases for any of said applications or proceedings;
 - (b) all disclosures of the subject matter of any of said applications or proceedings;
 - (c) all communications between the alleged inventor(s) and his patent attorney(s) or agent(s) concerning the subject matter described or claimed in any of said applications or proceedings;
 - (d) all documents referring or relating to any information used or supplied by the alleged Inventors in connection with the preparation or prosecution of any of said applications or proceedings including invention disclosures prepared by or for the inventor;
 - (e) all drafts of any of said applications or proceedings;
 - (f) all patents, publications, references, or prior art, and all records or documents referring or relating to any prior art or possible prior art, and all records or documents referring or relating to any prior art or any possible ground of

unpatentability and/or invalidity, submitted, cited, discussed or considered in connection with any of said applications or proceedings;

- (g) all documents referring or relating to the citation of, decision not to cite, or failure to cite, any references, co-pending applications, and/or prior art to the PTO or other patent office or patent authority in connections with said applications or proceedings; and
 - (h) all copies (including drafts) of responses to Office Actions, amendments, affidavits, declarations and other communications or submissions of any kind with or to the PTO or other patent office, or patent authority with respect to any of said applications or proceedings.
4. All documents and communications concerning secondary factors or objective indicia of non-obviousness with regard to the '078 patent, including, without limitation,
- (a) all documents and communications concerning any commercial success of products covered by the '078 patent and any asserted nexus with the claimed invention;
 - (b) all documents and communications concerning any long-felt need in the art that was satisfied by the invention in the '078 Patent;
 - (c) all documents and communications concerning whether or not others had tried, but failed to solve the problem solved by the invention claimed in the '078 Patent;
 - (d) all documents and communications concerning whether others have copied the invention claimed in the '078 Patent;
 - (e) all documents and communications concerning alleged superior, surprising or unexpected results achieved by the invention claimed in the '078 Patent; and

- (f) all documents and communications concerning whether others have accepted licenses under the patent in suit.
- 5. All documents and communications concerning whether or not the claimed invention was invented independently by other persons, regardless of whether or not such invention was before, during, or after the alleged invention by the inventors named on the '078 Patent.
- 6. All documents and communications concerning any proposal, consideration, or decision by Allergan and/or BioCide to draft and/or file foreign patent applications that correspond, in whole or in part, to the subject matter described or claimed as the invention in the '078 Patent.
- 7. All documents and communications concerning the alleged conception, reduction to practice, and development of the alleged invention claimed by the '078 Patent, including without limitation:
 - (a) all documents concerning any research, development, testing (both animal and human), and/or refinement of the subject matter of the '078 Patent;
 - (b) all documents referring or relating to the conception and/or reduction to practice of the alleged invention of the '078 Patent; and
 - (c) all documents concerning, created by, or created under the direction of the alleged Inventor of the '078 Patent, concerning the subject matter of the '078 Patent.
- 8. All documents and communications concerning any request, offer, acquisition or denial of any right (including any forbearance to assert a right), license, agreement, immunity, release, option, or interest in, to or under the '078 Patent, including all documents concerning why an agreement was not consummated (if not consummated), whether any

agreement has been terminated, and any documents relating to the transfer and/or assignment of rights under the '078 Patent or any foreign counterparts.

9. All documents and communications or opinions concerning the value, strategic or pecuniary, of the '078 Patent, any foreign counterparts and commercial embodiments of the alleged invention of the '078 Patent or counterparts, including documents concerning the developmental prospects for ophthalmic products, annual marketing reports, actual and estimated sales figures, and the like.
10. All documents concerning and/or identified by any prior art, patentability, novelty, validity, enforceability and/or infringement search, study, analysis, evaluation or opinion concerning any of the subject matter disclosed and/or claimed in the '078 Patent.
11. All documents concerning or relating to the receipt and/or transfer of any files relating to the '078 Patent.

B. The '790 Application and the '126 PCT Application

12. All documents concerning the '790 Application and the '126 PCT Application in your possession, custody, or control.
13. All documents contained in any file relating to the '790 Application and the '126 PCT Application.
14. All documents and communications that refer or relate to the preparation and/or prosecution of the '790 Application and/or the '126 PCT Application and/or any U.S. applications or foreign applications that constitute or are based in whole or in part on, or which claim priority from, or are the basis of priority for, the '790 Application and/or the '126 PCT Application and any related opposition, re-examination, and/or reissue proceedings, including, without limitation:

- (a) all documents that provided the bases for any of said applications or proceedings;
- (b) all disclosures of the subject matter of any of said applications or proceedings;
- (c) all communications between the alleged inventor(s) and his patent attorney(s) or agent(s) concerning the subject matter described or claimed in any of said applications or proceedings;
- (d) all documents referring or relating to any information used or supplied by the alleged Inventors in connection with the preparation or prosecution of any of said applications or proceedings including invention disclosures prepared by or for the inventor;
- (e) all drafts of any of said applications or proceedings;
- (f) all patents, publications, references, or prior art, and all records or documents referring or relating to any prior art or possible prior art, and all records or documents referring or relating to any prior art or any possible ground of unpatentability and/or invalidity, submitted, cited, discussed or considered in connection with any of said applications or proceedings;
- (g) all documents referring or relating to the citation of, decision not to cite, or failure to cite, any references, co-pending applications, and/or prior art to the PTO or other patent office or patent authority in connections with said applications or proceedings; and
- (h) all copies (including drafts) of responses to Office Actions, amendments, affidavits, declarations and other communications or submissions of any kind with or to the PTO or other patent office, or patent authority with respect to any of said applications or proceedings.

15. All documents and communications concerning whether or not the invention disclosed and/or claimed in the '790 Application and/or the '126 PCT Application was invented independently by other persons, regardless of whether or not such invention was before, during, or after the alleged invention by the inventor(s) named on the '790 Application and/or '126 PCT Application.
16. All documents and communications concerning any proposal, consideration, or decision by Bio-Cide and/or Allergan to draft and/or file foreign patent applications that correspond, in whole or in part, to the subject matter disclosed or claimed as the invention in the '790 Application and/or the '126 PCT Application.
17. All documents and communications concerning the alleged conception, reduction to practice, and development of the alleged invention disclosed and/or claimed by the '790 Application and/or the '126 PCT Application, including without limitation:
 - (a) all documents concerning any research, development, testing (both animal and human), and/or refinement of the subject matter of the '790 Application and/or the '126 PCT Application;
 - (b) all documents referring or relating to the conception and/or reduction to practice of the alleged invention of the '790 Application and/or the '126 PCT Application; and
 - (c) all documents concerning, created by, or created under the direction of the alleged Inventor(s) of the '790 Application and/or the '126 PCT Application, concerning the subject matter of the '790 Application and/or the '126 PCT Application.
18. All documents and communications concerning any request, offer, acquisition or denial of any right (including any forbearance to assert a right), license, agreement, immunity,

release, option, or interest in, to or under the '790 Application and/or the '126 PCT Application, including all documents concerning why an agreement was not consummated (if not consummated), whether any agreement has been terminated, and any documents relating to the transfer and/or assignment of rights under the '790 Application and/or the '126 PCT Application or any foreign counterpart applications and/or patents.

19. All documents and communications or opinions concerning the value, strategic or pecuniary, of the '790 Application and/or the '126 PCT Application, any foreign counterparts and commercial embodiments of the alleged invention of the '790 Application and/or the '126 PCT Application or counterpart applications and/or patents, including documents concerning the developmental prospects for ophthalmic products, annual marketing reports, actual and estimated sales figures, and the like.
20. All documents concerning and/or identified by any prior art, patentability, novelty, validity, enforceability and/or infringement search, study, analysis, evaluation or opinion concerning any of the subject matter disclosed and/or claimed in the '790 Application and/or the '126 PCT Application.
21. All documents concerning or relating to the receipt and/or transfer of any files relating to the '790 Application and/or the '126 PCT Application.

C. Correspondence Between Allergan and Bio-Cide

22. All documents and communications or opinions concerning or relating to Allergan's interest in, and use of, Purogene, Purite, or any stabilized chlorine dioxide component, including without limitation:

- (a) All correspondence between Bio-Cide and Allergan regarding Allergan's interest in, and use of, Purogene, Purite, or any stabilized chlorine dioxide component.
 - (b) All documents and communications concerning any proposal, consideration, or decision by Allergan regarding Allergan's interest in, and use of, Purogene, Purite, or any stabilized chlorine dioxide component.
23. All documents and communications concerning or relating to the March 2, 1983 letter from Clayton F. Lee at Bio-Cide to Allergan, including without limitation:
- (a) All enclosures and/or attachments to the March 2, 1983 letter.
 - (b) Any communications in response to the March 2, 1983 letter.
24. All documents and communications concerning or relating to the March 28, 1983 letter from Clayton F. Lee to Claude Anger at Allergan, including without limitation:
- (a) All enclosures and/or attachments to the March 28, 1983 letter.
 - (b) Any communications in response to the March 28, 1983 letter.
25. All documents and communications concerning or relating to the January 18, 1984 letter from A. Z. Dziabo at Allergan to Bio-Cide, including without limitation:
- (a) All enclosures and/or attachments to the January 18, 1984 letter.
 - (b) Any communications in response to the January 18, 1984 letter.

EXHIBIT B

AO88 (Rev. 12/06) Subpoena in a Civil Case

**Issued by the
UNITED STATES DISTRICT COURT**

WESTERN**DISTRICT OF****OKLAHOMA****In Re: Brimonidine Patent Litigation****SUBPOENA IN A CIVIL CASE**

v.

Case Number:¹ 07-MD-01866-GMS

TO: Bio-Cide International Inc.
2650 Venture Drive
Norman, OK 73069

Currently pending in the U.S.District
Court for the District of Delaware

- YOU ARE COMMANDED** to appear in the United States District court at the place, date, and time specified below to testify in the above case.

PLACE OF TESTIMONY	COURTROOM
	DATE AND TIME

- YOU ARE COMMANDED** to appear at the place, date, and time specified below to testify at the taking of a deposition in the above case.

PLACE OF DEPOSITION <small>Philip McFall McCaffrey McVay & Murrah P.C. Corporate Tower / Thirteenth Floor, 101 N. Robinson, Oklahoma City, OK 73102 (Please designate one or more representatives to testify on behalf of Bio-Cide International Inc. in accordance with Federal Rule of Civil Procedure 30(b)(6))</small>	DATE AND TIME Sept. 24, 2008 9:30 a.m.
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------

- YOU ARE COMMANDED** to produce and permit inspection and copying of the following documents or objects at the place, date, and time specified below (list documents or objects):

See Schedule A.

PLACE <small>Mr. Fred Leibrock, Phillips McFall McCaffrey McVay & Murrah P.C. Corporate Tower / Thirteenth Floor, 101 N. Robinson, Oklahoma City, OK 73102</small>	DATE AND TIME Sept. 17, 2008
PREMISES	DATE AND TIME

Any organization not a party to this suit that is subpoenaed for the taking of a deposition shall designate one or more officers, directors, or managing agents, or other persons who consent to testify on its behalf, and may set forth, for each person designated, the matters on which the person will testify. Federal Rules of Civil Procedure, 30(b)(6).

ISSUING OFFICER'S SIGNATURE AND TITLE (INDICATE IF ATTORNEY FOR PLAINTIFF OR DEFENDANT) 	DATE (Attorney for Defendant) Sept. 3, 2008
ISSUING OFFICER'S NAME, ADDRESS AND PHONE NUMBER Joanna Stevason, Katten Muchin Rosenman LLP, 525 W. Monroe St., Chicago, IL 60661 (312) 902-5200	

(See Rule 45, Federal Rules of Civil Procedure, Subdivisions (c), (d), and (e), on next page)

¹ If action is pending in district other than district of issuance, state district under case number.


PROOF OF SERVICE

SERVED	DATE	PLACE
SERVED	9/3/2008	1717 Main Street, Suite 5000, Dallas, TX 75201
SERVED ON (PRINT NAME)	MANNER OF SERVICE	
W. Chad Shear (on behalf of Bio-Cide International Inc.)	Federal Express	
SERVED BY (PRINT NAME)	TITLE	
Joanna Stevason	Attorney	

DECLARATION OF SERVER

I declare under penalty of perjury under the laws of the United States of America that the foregoing information contained in the Proof of Service is true and correct.

Executed on 9/3/2008
DATE



SIGNATURE OF SERVER

525 W. Monroe Street, Chicago, IL 60661
ADDRESS OF SERVER

Rule 45, Federal Rules of Civil Procedure, Subdivisions (c), (d), and (e), as amended on December 1, 2006:

(c) PROTECTION OF PERSONS SUBJECT TO SUBPOENAS.

(1) A party or an attorney responsible for the issuance and service of a subpoena shall take reasonable steps to avoid imposing undue burden or expense on a person subject to that subpoena. The court on behalf of which the subpoena was issued shall enforce this duty and impose upon the party or attorney in breach of this duty an appropriate sanction, which may include, but is not limited to, lost earnings and a reasonable attorney's fee.

(2) (A) A person commanded to produce and permit inspection, copying, testing, or sampling of designated electronically stored information, books, papers, documents or tangible things, or inspection of premises need not appear in person at the place of production or inspection unless commanded to appear for deposition, hearing or trial.

(B) Subject to paragraph (d)(2) of this rule, a person commanded to produce and permit inspection, copying, testing, or sampling may, within 14 days after service of the subpoena or before the time specified for compliance if such time is less than 14 days after service, serve upon the party or attorney designated in the subpoena written objection to producing any or all of the designated materials or inspection of the premises—or to producing electronically stored information in the form or forms requested. If objection is made, the party serving the subpoena shall not be entitled to inspect, copy, test, or sample the materials or inspect the premises except pursuant to an order of the court by which the subpoena was issued. If objection has been made, the party serving the subpoena may, upon notice to the person commanded to produce, move at any time for an order to compel the production, inspection, copying, testing, or sampling. Such an order to compel shall protect any person who is not a party or an officer of a party from significant expense resulting from the inspection, copying, testing, or sampling commanded.

(3) (A) On timely motion, the court by which a subpoena was issued shall quash or modify the subpoena if it

(i) fails to allow reasonable time for compliance;

(ii) requires a person who is not a party or an officer of a party to travel to a place more than 100 miles from the place where that person resides, is employed or regularly transacts business in person, except that, subject to the provisions of clause (c)(3)(B)(iii) of this rule, such a person may in order to attend trial be commanded to travel from any such place within the state in which the trial is held;

(iii) requires disclosure of privileged or other protected matter and no exception or waiver applies; or

(iv) subjects a person to undue burden.

(B) If a subpoena

(i) requires disclosure of a trade secret or other confidential research, development, or commercial information, or

(ii) requires disclosure of an unretained expert's opinion or information not describing specific events or occurrences in dispute and resulting from the expert's study made not at the request of any party, or

(iii) requires a person who is not a party or an officer of a party to incur substantial expense to travel more than 100 miles to attend trial, the court may, to protect a person subject

to or affected by the subpoena, quash or modify the subpoena or, if the party in whose behalf the subpoena is issued shows a substantial need for the testimony or material that cannot be otherwise met without undue hardship and assures that the person to whom the subpoena is addressed will be reasonably compensated, the court may order appearance or production only upon specified conditions.

(d) DUTIES IN RESPONDING TO SUBPOENA.

(1) (A) A person responding to a subpoena to produce documents shall produce them as they are kept in the usual course of business or shall organize and label them to correspond with the categories in the demand.

(B) If a subpoena does not specify the form or forms for producing electronically stored information, a person responding to a subpoena must produce the information in a form or forms in which the person ordinarily maintains it or in a form or forms that are reasonably usable.

(C) A person responding to a subpoena need not produce the same electronically stored information in more than one form.

(D) A person responding to a subpoena need not provide discovery of electronically stored information from sources that the person identifies as not reasonably accessible because of undue burden or cost. On motion to compel discovery or to quash, the person from whom discovery is sought must show that the information sought is not reasonably accessible because of undue burden or cost. If that showing is made, the court may nonetheless order discovery from such sources if the requesting party shows good cause, considering the limitations of Rule 26(b)(2)(C). The court may specify conditions for the discovery.

(2) (A) When information subject to a subpoena is withheld on a claim that it is privileged or subject to protection as trial-preparation materials, the claim shall be made expressly and shall be supported by a description of the nature of the documents, communications, or things not produced that is sufficient to enable the demanding party to contest the claim.

(B) If information is produced in response to a subpoena that is subject to a claim of privilege or of protection as trial-preparation material, the person making the claim may notify any party that received the information of the claim and the basis for it. After being notified, a party must promptly return, sequester, or destroy the specified information and any copies it has and may not use or disclose the information until the claim is resolved. A receiving party may promptly present the information to the court under seal for a determination of the claim. If the receiving party disclosed the information before being notified, it must take reasonable steps to retrieve it. The person who produced the information must preserve the information until the claim is resolved.

(e) CONTEMPT. Failure of any person without adequate excuse to obey a subpoena served upon that person may be deemed a contempt of the court from which the subpoena issued. An adequate cause for failure to obey exists when a subpoena purports to require a nonparty to attend or produce at a place not within the limits provided by clause (ii) of subparagraph (c)(3)(A).

SCHEDULE A

Pursuant to Federal Rules of Civil Procedure 30(b)(6) and 45, you are required to designate one or more officers, directors, or managing agents, or designate other persons who consent to testify on your behalf to appear for deposition concerning the following matters and to produce all non-privileged documents in your possession relating to the same:

DEFINITIONS AND INSTRUCTIONS

1. **'078 Patent.** The term “ ‘078 Patent” means U.S. Patent No. 5,424,078.
2. **‘640 Application.** The term “ ‘640 Application” means U.S. Patent Application No. 694,640 filed May 2, 1991.
3. **‘791 Application.** The term “ ‘791 Application” means U.S. Patent Application No. 277,791 filed Nov. 29, 1988.
4. **‘790 Application.** The term “ ‘790 Application” means U.S. Patent Application No. 277,790 filed on Nov. 29, 1988.
5. **‘126 PCT Application.** The term “ ‘126 PCT Application” means PCT Application No. WO 90/06126 filed Nov. 22, 1989 and published on June 14, 1990.
6. **Allergan.** The term “Allergan” refers to Allergan, Inc. and any related entities, partners, corporate parents, subsidiaries, affiliates, as well as any of their present or former officers, directors, employees, agents, representatives, attorneys and persons acting or purporting to act on their behalf. Where applicable, this definition shall include all persons having a former or current ownership interest in the ‘078 Patent, the ‘791 Application, and/or the ‘640 Application.

7. **Bio-Cide.** The term "Bio-Cide" refers to Bio-Cide International, Inc. and any related entities, partners, corporate parents, subsidiaries, affiliates, as well as any of their present or former officers, directors, employees, agents, representatives, attorneys and persons acting or purporting to act on their behalf. Where applicable, this definition shall include all persons having a former or current ownership interest in the '790 Application and/or the '126 PCT Application.
8. **Communication.** The term "communication" means the transmittal of information in the form of facts, ideas, inquiries, or otherwise.
9. **Concern(s), Concerning, Concerned with, Relate(s) or Relating to.** The terms "concern(s)", "concerning", "concerned with", "relate(s)", or "relating to" are used interchangeably and mean concerning, evidencing, pertaining to, referring to, mentioning, memorializing, commenting on, containing, identifying, connected with, contemplating, discussing, stating, describing, reflecting, dealing with, consisting of, constituting, comprising, recording, or being relevant to all or any portion of the specified fact, conditions, events, or incidents.
10. **Date.** The term "date" means the exact day, month, and year, if known or ascertainable; if the exact day, month, and year are not known or ascertainable, the most accurate temporal reference available.
11. **Document.** The term "document" is synonymous in meaning and equal in scope to the usage of this term in Federal Rule of Civil Procedure 34(a), including, without limitation, electronic or computerized data compilations. A draft or non-identical copy is a separate document within the meaning of this term. "Document" also includes and refers to the

file or any container which once held any documents, as well as to any writing or printing which might appear on such file or container.

12. **Inventor(s).** The term "inventor" or "inventors" means the named inventor(s) of the '078 Patent, the '640 Application, the '791 Application, the '790 Application, the '126 PCT Application, Anthony J. Dziabo, Paul S. Ripley, Bobby C. Danner, and/or Persons with a past or present ownership interest in the '790 Application, the '126 PCT Application and/or the application which matured into the '078 patent and/or the '078 patent itself, including, without limitation, Allergan and/or Bio-Cide and (i) all their predecessors-in-interest and successors-in-interest; (ii) all past or present corporate parents, subsidiaries, affiliates divisions, officers, directors, employees, agents, consultants, investigators, attorneys, and representatives; (iii) any other person acting on their behalf or on whose behalf they have acted or are acting; or (iv) any other person or entity otherwise subject to their control or which controls or controlled them.
13. **Person.** The term "person" is defined as any natural person or any business, legal or governmental entity or association, and any functional division thereof.
14. **You.** The term "you" or "your" refers to Bio-Cide International Inc., and any past or present employees, agents, representatives, or attorneys with knowledge, possession, custody or control of any documents relating to the '078 Patent, the '791 Application, the '640 Application, the '790 Application, and/or the '126 PCT Application.
15. The following rules of construction apply to these document requests, definitions, and instructions:

- (a) **All/Each/Any.** The terms "all", "each", and "any" shall be construed as inclusive and synonymous and are as inclusive in scope as permitted by the Federal Rules of Civil Procedure.
 - (b) **And/Or.** The connectives "and" and "or" shall be construed either disjunctively or conjunctively as necessary to bring within the scope of the request all responses that might otherwise be construed to be outside of its scope.
 - (c) **Number.** The use of the singular form of any word includes the plural and vice versa.
 - (d) **Independence.** Except as otherwise expressly directed herein, each paragraph and subparagraph of a document request shall be construed independently and not by reference to any other paragraph or subparagraph herein for the purpose of limiting the scope of the document request being responded to.
16. Each request to produce documents shall be construed to request documents within your possession, custody, or control. Separately, for each Request, if any document responsive to that Request once was in your possession, custody, or control but has been lost, discarded, destroyed, or is otherwise presently not within your possession, custody, or control:
- (a) identify the unavailable document;
 - (b) identify any and all persons who lost, discarded, or destroyed the document or caused the document to become otherwise unavailable;
 - (c) identify any and all persons likely to have knowledge concerning the circumstances by which the document was lost, discarded, destroyed, or otherwise became unavailable; and

- (d) identify any and all persons likely to have knowledge concerning the contents of the document that was lost, discarded, destroyed, or otherwise became unavailable.
- 17. When producing documents, you should organize and label them to correspond with the numbered categories in this request and where applicable, the order and organization of documents within each category should reflect the manner in which such documents are maintained in the usual course of business.
- 18. Please produce all documents maintained or stored electronically in native, electronic format with all relevant metadata intact and in appropriate useable manner. Encrypted or password protected documents should be produced in a form permitting them to be reviewed.
- 19. If you find the meaning of any terms in these requests unclear, you shall assume a reasonable meaning, state what the assumed meaning is, and respond to the request according to the assumed meaning.
- 20. If you object to any request or part of any request, the reason(s) for the objection shall be stated in full. If an objection is made to any request, production should be made of all documents or things to which the objection does not relate.
- 21. If you withhold any information, document, or thing otherwise discoverable under the Federal Rules of Civil Procedure on the basis of privilege and/or the work product doctrine, the following information is requested:
 - (a) the privilege and/or work product rule of law being relied upon;
 - (b) the date the document was created;

- (c) the identity of the person or persons who created the information, document or thing;
- (d) the identity of the present custodian of the information, document or thing; and
- (e) the identity of any and all persons to whom the information, document, or thing was or has been sent, distributed, forwarded, copied, told, or communicated in any manner, stating the job title and/or position of that person;
- (f) the subject matter of the information, document or thing; and
- (g) the location of the information, document or thing.

DOCUMENT REQUESTS AND MATTERS FOR EXAMINATION

A. The '078 Patent

- 1. All documents concerning the '078 Patent in your possession, custody, or control.
- 2. All documents contained in any file relating to the '078 Patent.
- 3. All documents and communications that refer or relate to the preparation and/or prosecution of the '078 Patent and/or any U.S. applications or foreign applications that constitute or are based in whole or in part on, or which claim priority from, or are the basis of priority for, any of the applications in the family of patent application leading to the '078 Patent (including the '791 and '640 Applications) and any related opposition, re-examination, and/or reissue proceedings, including, without limitation:
 - (a) all documents that provided the bases for any of said applications or proceedings;
 - (b) all disclosures of the subject matter of any of said applications or proceedings;
 - (c) all communications between the alleged inventor(s) and his patent attorney(s) or agent(s) concerning the subject matter described or claimed in any of said applications or proceedings;

- (d) all documents referring or relating to any information used or supplied by the alleged Inventors in connection with the preparation or prosecution of any of said applications or proceedings including invention disclosures prepared by or for the inventor;
 - (e) all drafts of any of said applications or proceedings;
 - (f) all patents, publications, references, or prior art, and all records or documents referring or relating to any prior art or possible prior art, and all records or documents referring or relating to any prior art or any possible ground of unpatentability and/or invalidity, submitted, cited, discussed or considered in connection with any of said applications or proceedings;
 - (g) all documents referring or relating to the citation of, decision not to cite, or failure to cite, any references, co-pending applications, and/or prior art to the PTO or other patent office or patent authority in connections with said applications or proceedings; and
 - (h) all copies (including drafts) of responses to Office Actions, amendments, affidavits, declarations and other communications or submissions of any kind with or to the PTO or other patent office, or patent authority with respect to any of said applications or proceedings.
4. All documents and communications concerning secondary factors or objective indicia of non-obviousness with regard to the '078 patent, including, without limitation,
- (a) all documents and communications concerning any commercial success of products covered by the '078 patent and any asserted nexus with the claimed invention;

- (b) all documents and communications concerning any long-felt need in the art that was satisfied by the invention in the '078 Patent;
 - (c) all documents and communications concerning whether or not others had tried, but failed to solve the problem solved by the invention claimed in the '078 Patent;
 - (d) all documents and communications concerning whether others have copied the invention claimed in the '078 Patent;
 - (e) all documents and communications concerning alleged superior, surprising or unexpected results achieved by the invention claimed in the '078 Patent; and
 - (f) all documents and communications concerning whether others have accepted licenses under the patent in suit.
5. All documents and communications concerning whether or not the claimed invention was invented independently by other persons, regardless of whether or not such invention was before, during, or after the alleged invention by the inventors named on the '078 Patent.
6. All documents and communications concerning any proposal, consideration, or decision by Allergan and/or BioCide to draft and/or file foreign patent applications that correspond, in whole or in part, to the subject matter described or claimed as the invention in the '078 Patent.
7. All documents and communications concerning the alleged conception, reduction to practice, and development of the alleged invention claimed by the '078 Patent, including without limitation:
- (a) all documents concerning any research, development, testing (both animal and human), and/or refinement of the subject matter of the '078 Patent;

- (b) all documents referring or relating to the conception and/or reduction to practice of the alleged invention of the '078 Patent; and
 - (c) all documents concerning, created by, or created under the direction of the alleged Inventor of the '078 Patent, concerning the subject matter of the '078 Patent.
8. All documents and communications concerning any request, offer, acquisition or denial of any right (including any forbearance to assert a right), license, agreement, immunity, release, option, or interest in, to or under the '078 Patent, including all documents concerning why an agreement was not consummated (if not consummated), whether any agreement has been terminated, and any documents relating to the transfer and/or assignment of rights under the '078 Patent or any foreign counterparts.
9. All documents and communications or opinions concerning the value, strategic or pecuniary, of the '078 Patent, any foreign counterparts and commercial embodiments of the alleged invention of the '078 Patent or counterparts, including documents concerning the developmental prospects for ophthalmic products, annual marketing reports, actual and estimated sales figures, and the like.
10. All documents concerning and/or identified by any prior art, patentability, novelty, validity, enforceability and/or infringement search, study, analysis, evaluation or opinion concerning any of the subject matter disclosed and/or claimed in the '078 Patent.
11. All documents concerning or relating to the receipt and/or transfer of any files relating to the '078 Patent.

B. The '790 Application and the '126 PCT Application

12. All documents concerning the '790 Application and the '126 PCT Application in your possession, custody, or control.

13. All documents contained in any file relating to the '790 Application and the '126 PCT Application.
14. All documents and communications that refer or relate to the preparation and/or prosecution of the '790 Application and/or the '126 PCT Application and/or any U.S. applications or foreign applications that constitute or are based in whole or in part on, or which claim priority from, or are the basis of priority for, the '790 Application and/or the '126 PCT Application and any related opposition, re-examination, and/or reissue proceedings, including, without limitation:
 - (a) all documents that provided the bases for any of said applications or proceedings;
 - (b) all disclosures of the subject matter of any of said applications or proceedings;
 - (c) all communications between the alleged inventor(s) and his patent attorney(s) or agent(s) concerning the subject matter described or claimed in any of said applications or proceedings;
 - (d) all documents referring or relating to any information used or supplied by the alleged Inventors in connection with the preparation or prosecution of any of said applications or proceedings including invention disclosures prepared by or for the inventor;
 - (e) all drafts of any of said applications or proceedings;
 - (f) all patents, publications, references, or prior art, and all records or documents referring or relating to any prior art or possible prior art, and all records or documents referring or relating to any prior art or any possible ground of unpatentability and/or invalidity, submitted, cited, discussed or considered in connection with any of said applications or proceedings;

- (g) all documents referring or relating to the citation of, decision not to cite, or failure to cite, any references, co-pending applications, and/or prior art to the PTO or other patent office or patent authority in connections with said applications or proceedings; and
 - (h) all copies (including drafts) of responses to Office Actions, amendments, affidavits, declarations and other communications or submissions of any kind with or to the PTO or other patent office, or patent authority with respect to any of said applications or proceedings.
15. All documents and communications concerning whether or not the invention disclosed and/or claimed in the '790 Application and/or the '126 PCT Application was invented independently by other persons, regardless of whether or not such invention was before, during, or after the alleged invention by the inventor(s) named on the '790 Application and/or '126 PCT Application.
16. All documents and communications concerning any proposal, consideration, or decision by Bio-Cide and/or Allergan to draft and/or file foreign patent applications that correspond, in whole or in part, to the subject matter disclosed or claimed as the invention in the '790 Application and/or the '126 PCT Application.
17. All documents and communications concerning the alleged conception, reduction to practice, and development of the alleged invention disclosed and/or claimed by the '790 Application and/or the '126 PCT Application, including without limitation:
- (a) all documents concerning any research, development, testing (both animal and human), and/or refinement of the subject matter of the '790 Application and/or the '126 PCT Application;

- (b) all documents referring or relating to the conception and/or reduction to practice of the alleged invention of the '790 Application and/or the '126 PCT Application; and
 - (c) all documents concerning, created by, or created under the direction of the alleged Inventor(s) of the '790 Application and/or the '126 PCT Applicaiton, concerning the subject matter of the '790 Application and/or the '126 PCT Application.
18. All documents and communications concerning any request, offer, acquisition or denial of any right (including any forbearance to assert a right), license, agreement, immunity, release, option, or interest in, to or under the '790 Application and/or the '126 PCT Application, including all documents concerning why an agreement was not consummated (if not consummated), whether any agreement has been terminated, and any documents relating to the transfer and/or assignment of rights under the '790 Application and/or the '126 PCT Application or any foreign counterpart applications and/or patents.
19. All documents and communications or opinions concerning the value, strategic or pecuniary, of the '790 Application and/or the '126 PCT Application, any foreign counterparts and commercial embodiments of the alleged invention of the '790 Application and/or the '126 PCT Application or counterpart applications and/or patents, including documents concerning the developmental prospects for ophthalmic products, annual marketing reports, actual and estimated sales figures, and the like.
20. All documents concerning and/or identified by any prior art, patentability, novelty, validity, enforceability and/or infringement search, study, analysis, evaluation or opinion

concerning any of the subject matter disclosed and/or claimed in the '790 Application and/or the '126 PCT Application.

21. All documents concerning or relating to the receipt and/or transfer of any files relating to the '790 Application and/or the '126 PCT Application.

C. Correspondence Between Allergan and Bio-Cide

22. All documents and communications or opinions concerning or relating to Allergan's interest in, and use of, Purogene, Purite, or any stabilized chlorine dioxide component, including without limitation:
 - (a) All correspondence between Bio-Cide and Allergan regarding Allergan's interest in, and use of, Purogene, Purite, or any stabilized chlorine dioxide component.
 - (b) All documents and communications concerning any proposal, consideration, or decision by Allergan regarding Allergan's interest in, and use of, Purogene, Purite, or any stabilized chlorine dioxide component.
23. All documents and communications concerning or relating to the March 2, 1983 letter from Clayton F. Lee at Bio-Cide to Allergan, including without limitation:
 - (a) All enclosures and/or attachments to the March 2, 1983 letter.
 - (b) Any communications in response to the March 2, 1983 letter.
24. All documents and communications concerning or relating to the March 28, 1983 letter from Clayton F. Lee to Claude Anger at Allergan, including without limitation:
 - (a) All enclosures and/or attachments to the March 28, 1983 letter.
 - (b) Any communications in response to the March 28, 1983 letter.
25. All documents and communications concerning or relating to the January 18, 1984 letter from A. Z. Dziabo at Allergan to Bio-Cide, including without limitation:

- (a) All enclosures and/or attachments to the January 18, 1984 letter.
- (b) Any communications in response to the January 18, 1984 letter.

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

CERTIFICATE OF SERVICE

I, David E. Moore, hereby certify that on September 4, 2008, the attached document was electronically filed with the Clerk of the Court using CM/ECF which will send notification to the registered attorney(s) of record that the document has been filed and is available for viewing and downloading.

I further certify that on September 4, 2008, the attached document was Electronically Mailed to the following person(s):

Frederick L. Cottrell III
 Kelly E. Farnan
 Richards Layton & Finger
 One Rodney Square
 920 North King Street
 P.O. Box 551
 Wilmington, Delaware 19899
cottrell@rlf.com
Farnan@rlf.com

William J. Marsden, Jr.
 Susan M. Coletti
 Fish & Richardson P.C.
 919 N. Market Street, Suite 1100
 P.O. Box 1114
 Wilmington, DE 19899
marsden@fr.com
coletti@fr.com

William Chad Shear
 Fish and Richardson P.C.
 1717 Main Street, Suite 5000
 Dallas, TX 75201
czs@fr.com

Juanita Brooks
 Joseph P. Reid
 Fish & Richardson P.C.
 12390 El Camino Real
 San Diego, CA 92130
brooks@fr.com
reid@fr.com

Barry S. White
 Daniel G. Brown
 David A. Zwally
 Brian J. Malkin
 Frommer Lawrence & Haug LLP
 745 Fifth Avenue
 New York, New York 10151
bwhite@flhllaw.com
dbrown@flhllaw.com
dzwally@flhllaw.com
bmalkin@flhllaw.com

Jonathan E. Singer
 Michael J. Kane
 Deanna J. Reichel
 Fish & Richardson P.C.
 300 Dain Rauscher Plaza
 60 South Sixth Street
 Minneapolis, MN 55402
singer@fr.com
kane@fr.com
reichel@fr.com

Steven C. Carlson
Fish & Richardson P.C.
500 Arguello Street, Suite 500
Redwood City, CA 94063
steven.carlson@fr.com

Sharon E. Crane
Erin M. Dunston
Krista Leigh Lynch
Bingham McCutchen LLP
2020 K. Street NW
Washington, DC 20006-1806
sharon.crane@bingham.com
erin.dunston@bingham.com
krista.lynch@bingham.com

I further certify that on September 4, 2008, the attached document was sent via First Class Mail to the following person(s):

Jeffrey N. Luthi
Clerk, MDL Judicial Panel
One Columbus Circle, N.E.
Room G-255, Feder Judiciary Bldg.
Washington, DC 20002-8004

By: /s/ David E. Moore
Richard L. Horwitz
David E. Moore
Hercules Plaza, 6th Floor
1313 N. Market Street
Wilmington, Delaware 19899-0951
(302) 984-6000
rhorwitz@potteranderson.com
dmoore@potteranderson.com

834839 / 31920 / MDL